Investigators identified candidate protein markers from aptamer-based proteomic profiles of samples from women with or without late-onset preeclampsia.
In Nature this week: fetal variants influence maternal risk of preeclampsia, and more.
A genome-wide association study of children whose mothers had preeclampsia, conducted as part of the InterPregGen study, implicates variants near the FLT1 gene in the condition.
The planned test will be based on LifeCodexx's methylation-specific quantitative PCR technology.
In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.
Using absolute and relative gene expression analyses, researchers identified expression patterns associated with preeclampsia in dozens of placental tissue samples.
The money will be used to complete development of the preeclampsia test PrePsia and to commercialize an in-licensed metabolomic biomarker technology.
Roche's molecular diagnostics business, which makes up 17 percent of its overall diagnostics sales, grew 11 percent, driven by virology testing and sequencing.
The prospective study found the markers were able to rule out a woman's chance of developing preeclampsia with a negative predictive value of 99.3 percent.
Members of the small hunter-gatherer group from sub-Saharan Africa carry killer-cell immunoglobulin-like receptor alleles that appear to alter immune function in ways that benefit pregnancy.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.